News
EDSA
3.895
+4.70%
0.175
Weekly Report: what happened at EDSA last week (0928-1002)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at EDSA last week (0921-0925)?
Weekly Report · 09/28 09:09
Weekly Report: what happened at EDSA last week (0914-0918)?
Weekly Report · 09/21 09:09
Weekly Report: what happened at EDSA last week (0907-0911)?
Weekly Report · 09/14 09:09
Weekly Report: what happened at EDSA last week (0831-0904)?
Weekly Report · 09/07 09:09
Weekly Report: what happened at EDSA last week (0824-0828)?
Weekly Report · 08/31 09:10
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 08/26 17:06
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/24 21:06
Weekly Report: what happened at EDSA last week (0817-0821)?
Weekly Report · 08/24 09:10
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/20 12:06
Edesa Biotech Stock Sinks After Fresh Capital Raise
Benzinga · 08/20 10:20
Edesa Biotech 3.87M share Spot Secondary priced at $5.50
TipRanks · 08/20 10:11
Edesa Biotech prices $25M equity offering
Seeking Alpha · 08/20 07:32
Edesa Biotech Prices $25 Mln Public Offering Of Shares And Warrants; Stock Down
NASDAQ · 08/20 05:50
Edesa Biotech Raises $25 Million in Public Offering to Advance Immuno-Inflammatory Pipeline
TipRanks · 08/20 04:40
*Edesa Biotech Offering 3.9M Shares and Accompanying Warrants >EDSA
Dow Jones · 08/20 02:38
*Edesa Biotech Plans to Use Net Proceeds From Offering for General Corporate Purposes >EDSA
Dow Jones · 08/20 02:38
*Edesa Biotech Expects Offering to Close on or About Aug. 21 >EDSA
Dow Jones · 08/20 02:38
*Edesa Biotech Also Offering Pre-Funded Warrants >EDSA
Dow Jones · 08/20 02:38
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.